ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer
Ovarian Epithelial Carcinoma
Colorectal Cancer

Endometrial Cancer trials near Barcelona, CT, ESP:

Atezolizumab Trial in Endometrial Cancer - AtTEnd

Phase Ia study of Atezolizumab (NCT01375842) monotherapy in relapsed endometrial cancer were reported as abstract at ASCO 2017. Fif...

Active, not recruiting
Endometrial Cancer
Drug: Placebos
Drug: Atezolizumab

Phase 3

Mario Negri Institute for Pharmacological Research

Barcelona, Spain and 92 other locations

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Doxorubicin

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 223 other locations

for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...

Active, not recruiting
Endometrial Cancer
Drug: Matching placebo for selinexor
Drug: Selinexor

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Barcelona, Spain and 77 other locations

study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial...

Enrolling
Endometrial Cancer
Drug: Carboplatin-Paclitaxel
Drug: Dostarlimab

Phase 3

ARCAGY/ GINECO GROUP

Badalona, Spain and 94 other locations

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...

Enrolling
Endometrial Cancer
Drug: Navtemadlin
Drug: Navtemadlin Placebo

Phase 2, Phase 3

Kartos Therapeutics
Kartos Therapeutics

Barcelona, Spain and 82 other locations

(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...

Active, not recruiting
Endometrial Neoplasms
Drug: Carboplatin
Biological: durvalumab

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 202 other locations

participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....

Active, not recruiting
Neoplasms
Drug: Paclitaxel
Drug: Carboplatin

Phase 3

Tesaro
Tesaro

Barcelona, Spain and 168 other locations

choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...

Active, not recruiting
Endometrial Neoplasms
Drug: Doxorubicin
Drug: Paclitaxel

Phase 3

Eisai
Eisai

Barcelona, Spain and 168 other locations

drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

Phase 1

Lilly
Lilly

Barcelona, Spain and 73 other locations

who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, e....

Enrolling
Endometrial Cancer
Esophageal Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

Phase 1

Adaptimmune

Barcelona, Spain and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems